<SEC-DOCUMENT>0001047469-18-005782.txt : 20180824
<SEC-HEADER>0001047469-18-005782.hdr.sgml : 20180824
<ACCEPTANCE-DATETIME>20180824080644
ACCESSION NUMBER:		0001047469-18-005782
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20180824
DATE AS OF CHANGE:		20180824
EFFECTIVENESS DATE:		20180824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226992
		FILM NUMBER:		181035861

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>a2236544zs-3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg75801_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As filed with the Securities and Exchange Commission on August&nbsp;24, 2018  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-3<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>PTC THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 04-3416587</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>100 Corporate Court<BR>
South Plainfield, NJ 07080<BR>
(908)&nbsp;222-7000</B></FONT><FONT SIZE=1><BR>
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Stuart W. Peltz, Ph.D.<BR>
Chief Executive Officer<BR>
PTC Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080<BR>
(908)&nbsp;222-7000<BR>  </B></FONT><FONT SIZE=1>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="46%" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Brian A. Johnson<BR>
Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP<BR>
7 World Trade Center<BR>
250 Greenwich Street<BR>
New York, New York 10007<BR>
Telephone: (212)&nbsp;230-8800<BR>
Fax: (212)&nbsp;526-8888</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Mark E. Boulding<BR>
Executive Vice President and Chief Legal Officer<BR>
PTC Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080-2449<BR>
Telephone: (908)&nbsp;222-7000<BR>
Fax: (908)&nbsp;222-1128</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public:<BR>
From time to time after this registration statement becomes effective.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a registration statement pursuant to General Instruction&nbsp;I.D or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D filed to register additional securities or
additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="87pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="121pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be Registered(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price Per<BR>
Unit(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, par value $0.001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>3,500,907</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$43.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$151,869,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$18,908</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
shares of common stock will be offered for resale by the selling stockholders. Pursuant to Rule&nbsp;416 under the Securities Act, this Registration Statement
also relates to an indeterminate number of additional shares of common stock to be issued as a result of stock splits, stock dividends or similar transactions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
solely for purposes of calculating the registration fee pursuant to Rule&nbsp;457(c) under the Securities Act, based on average of high and low price per
share of the common stock as reported on the Nasdaq Global Select Market on August&nbsp;22, 2018.  </FONT></DD></DL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=609439,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]BA75801A.;16',USER='CHE109577',CD='23-AUG-2018;17:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>3,500,907 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g337856.jpg" ALT="LOGO" WIDTH="169" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>PTC Therapeutics,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to resales of shares of common stock previously issued by PTC Therapeutics,&nbsp;Inc. to the former stockholders of
Agilis Biotherapeutics,&nbsp;Inc., or Agilis, in connection with our acquisition of that company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will not receive any proceeds from the sale of the shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders identified in this prospectus, or their pledgees, assignees, donees, transferees or other successors-in-interest, may offer the shares from time to time through
public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is traded on the Nasdaq Global Select Market under the symbol "PTCT." On August&nbsp;23, 2018, the closing sale price of the common stock on the Nasdaq Global Select
Market was $44.52 per share. You are urged to obtain current market quotations for the common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our common stock involves significant risks. See the information contained in this prospectus under the heading "Risk Factors"
beginning on page&nbsp;8 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to
purchase our common stock.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><B>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</b></font></p><p align=center style="font-family:times;"><font></FONT><FONT SIZE=2><B>The date of this prospectus is August&nbsp;24, 2018.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=875545,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]BC75801A.;7',USER='CHE109577',CD='23-AUG-2018;17:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG75801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg75801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG75801_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi75801_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi75801_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi75801_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi75801_special_note_regarding_forward-looking_statements"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca75801_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca75801_prospectus_summary"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da75801_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da75801_risk_factors"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da75801_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da75801_use_of_proceeds"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da75801_selling_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING STOCKHOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da75801_selling_stockholders"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_description_of_capital_stock"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_plan_of_distribution"><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS.&nbsp;</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_legal_matters"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_experts"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_where_you_can_find_more_information"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc75801_incorporation_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc75801_incorporation_by_reference"><FONT SIZE=2>20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=720093,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]BG75801A.;6',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi75801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi75801_about_this_prospectus"> </A>
<A NAME="toc_bi75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC. The selling stockholders
may from time to time sell shares of common stock described in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides you with a description of the common stock selling stockholders may offer. You should read both this prospectus together with the additional information
described under the heading "Where You Can Find More Information" beginning on page&nbsp;19 of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized anyone to provide you with information different from that contained in this prospectus, any accompanying prospectus supplement or in any related free writing
prospectus filed by us with the SEC. We do not take any responsibility for, and cannot provide any assurance as to the
reliability of, any information other than the information in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. This
prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described herein or an offer to sell or the solicitation of an offer to
buy such securities in any circumstances in which such offer or solicitation is unlawful. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in
jurisdictions where offers and sales are permitted. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any
related free writing prospectus is accurate only as of the respective dates of such documents. Our business, financial condition, results of operations and prospects may have changed materially since
those dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context otherwise indicates, references in this prospectus to "PTC," "we," "our," "us" and "the Company" refer, collectively, to PTC Therapeutics,&nbsp;Inc., a Delaware
corporation, and its consolidated subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi75801_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_bi75801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus and the information incorporated by reference in this prospectus include "forward-looking statements" within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements
contained or incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth, other than statements of historical facts, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might,"
"plan," "predict," "project," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
forward-looking statements in this prospectus and the information incorporated by reference herein and therein include, among other things, statements
about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our ability to realize the anticipated benefits of our acquisition of Agilis, including the possibility that the expected impact of benefits
from the acquisition, including with respect to the business of Agilis and our expectations with respect to the potential achievement of development, regulatory and sales milestones and our contingent
payments to the former Agilis equityholders with respect thereto, will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of
Agilis's operations and employees into our business, our ability to obtain marketing approval of our gene therapy for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or
GT-AADC, and other product candidates we acquired from Agilis, unknown liabilities, the risk of litigation </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=600887,FOLIO='1',FILE='DISK108:[18ZCO1.18ZCO75801]BI75801A.;6',USER='CHE109577',CD='23-AUG-2018;17:47' -->
<A NAME="page_bi75801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>and/or
regulatory actions related to the acquisition, and other business effects, including the effects of industry, market, economic, political or regulatory conditions; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all,
with third-party payors for Emflaza&#153; (deflazacort) for the treatment of Duchenne muscular dystrophy, or DMD, in the United States and for Translarna&#153; (ataluren) for the
treatment of nonsense mutation DMD, or nmDMD, in the European Economic Area, or EEA, and other countries in which we have or may obtain regulatory approval, or in which there exist significant
reimbursed early access programs, or EAP programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain our marketing authorization of Translarna for the treatment of nmDMD in the EEA (which is subject to the specific
obligation to conduct and submit the results of Study 041 to the European Medicines Agency, or EMA, and annual review and renewal by the European Commission following reassessment of the benefit-risk
balance of the authorization by the EMA); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to enroll, fund, and complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of
Translarna for the treatment of nmDMD followed by an 18-month open label extension, according to the protocol agreed with the EMA, and by the trial's deadline; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the anticipated period of market exclusivity for Emflaza for the treatment of DMD in the United States under the Orphan Drug Act of 1983, or
the Orphan Drug Act, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act and through any grant of pediatric exclusivity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to complete the United States Food and Drug Administration, or FDA, post-marketing requirements to the marketing authorization of
Emflaza or any requirements necessary to obtain any grant of pediatric exclusivity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations with respect to our acquisition of all rights to Emflaza from Marathon Pharmaceuticals,&nbsp;LLC (now known as Complete
Pharma Holdings,&nbsp;LLC), or Marathon, including with respect to our ability to realize the anticipated benefits of the acquisition (including with respect to future revenue generation and
contingent payments to Marathon based on annual net sales); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to complete any dystrophin study necessary in order to resolve the matters set forth in the FDA's denial of our appeal to the
Complete Response Letter we received from the FDA in connection with our New Drug Application, or NDA, for Translarna for the treatment of nmDMD, and our ability to perform additional clinical trials,
non-clinical studies or CMC assessments or analyses at significant cost; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and scope of our continued commercialization of Translarna as a treatment for nmDMD in the EEA or other territories outside of the
United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of
nmDMD on adequate terms, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations and the potential financial impact and benefits related to our Collaboration and Licensing Agreement with Akcea
Therapeutics,&nbsp;Inc., or Akcea, including with respect to the timing of regulatory approval of Tegsedi<SUP>TM</SUP> (inotersen) and Waylivra<SUP>TM</SUP> (volanesorsen) in countries where
we are licensed to commercialize them, the potential commercialization of Tegsedi and Waylivra, and our expectations with respect to contingent payments to Akcea based on the potential achievement of
certain regulatory milestones and royalty payments by us to Akcea based on our potential achievement of certain net sales thresholds; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=628827,FOLIO='2',FILE='DISK108:[18ZCO1.18ZCO75801]BI75801A.;6',USER='CHE109577',CD='23-AUG-2018;17:47' -->
<A NAME="page_bi75801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding the potential market opportunity for Translarna, Emflaza, GT-AADC, Tegsedi, Waylivra or any other product candidate,
including the size of eligible patient populations and our ability to identify such patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing,
including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and conduct of our ongoing, planned and potential future clinical trials and studies of Translarna for the treatment of nmDMD,
aniridia, and Dravet syndrome/CDKL5, each caused by nonsense mutations, as well as our studies in spinal muscular atrophy and our oncology program, including the timing of initiation, enrollment and
completion of the trials and the period during which the results of the trials will become available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate and degree of market acceptance and clinical utility of Translarna, Emflaza, GT-AADC, Tegsedi and Waylivra, and our other product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and
reimbursement negotiations in the applicable territory do not have a positive outcome; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of, and our ability to obtain additional marketing authorizations for, Translarna and our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability of Translarna, Emflaza, GT-AADC, Tegsedi and Waylivra and our other product candidates to meet existing or future regulatory
standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain the current labeling under the marketing authorization in the EEA or expand the approved product label of Translarna
for the treatment of nmDMD; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential receipt of revenues from future sales of Translarna, Emflaza and other product candidates, including our ability to earn a profit
from sales or licenses of Translarna for the treatment of nmDMD in the countries in which we have or may obtain regulatory approval and of Emflaza for the treatment of DMD in the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential impact that enrollment, funding and completion of Study 041 may have on our revenue growth; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and
deliver Translarna and Emflaza and any other product candidate in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy
their other obligations to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish and maintain arrangements for the manufacture of Translarna, Emflaza and our other product candidates that are
sufficient to meet clinical trial and commercial launch requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to satisfy our obligations under the terms of the credit and security agreement with MidCap Financial Trust, or MidCap Financial,
as administrative agent and MidCap Financial and certain other financial institutions as lenders thereunder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our other regulatory submissions, including with respect to timing and outcome of regulatory review; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to pursue development of Translarna for additional indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to advance our earlier stage programs, including our oncology program; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=903745,FOLIO='3',FILE='DISK108:[18ZCO1.18ZCO75801]BI75801A.;6',USER='CHE109577',CD='23-AUG-2018;17:47' -->
<A NAME="page_bi75801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to pursue research and development of other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets
and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential advantages of Translarna, Emflaza, GT-AADC, Tegsedi and Waylivra and any other product candidate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our intellectual property position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of government laws and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of litigation that has been brought against us and certain of our current and former officers or of litigation that we are pursuing
against others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitive position; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations with respect to the development and regulatory status of our product candidates and program directed against spinal muscular
atrophy in collaboration with F.&nbsp;Hoffmann La Roche&nbsp;Ltd and Hoffmann La Roche&nbsp;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA
Foundation, and our estimates regarding future revenues from achievement of milestones in that program. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not actually achieve the plans, intentions or expectations expressed or implied in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the
forward-looking statements we make. These important factors include our "critical accounting estimates" described in Part&nbsp;II, Item&nbsp;7 "Management's Discussion and Analysis of Financial
Condition and Results of Operations&#151;Critical Accounting Policies and Significant Judgments and Estimates" of our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2017 and the factors set forth under the caption "Risk Factors" in Part&nbsp;I, Item&nbsp;1A of our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2017, under the caption "Risk Factors" in Part&nbsp;II, Item&nbsp;1A of our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2018 and
June&nbsp;30, 2018, and in Exhibit&nbsp;99.2 to our Current Report on Form&nbsp;8-K filed on August&nbsp;24, 2018. Although we may elect to update forward-looking statements in the future, we
specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the
date of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=338041,FOLIO='4',FILE='DISK108:[18ZCO1.18ZCO75801]BI75801A.;6',USER='CHE109577',CD='23-AUG-2018;17:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca75801_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca75801_prospectus_summary"> </A>
<A NAME="toc_ca75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate by reference. This
summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus carefully, especially the risks of investing in our
common stock discussed under "Risk Factors" beginning on page&nbsp;8 of this prospectus, under the caption "Risk Factors" in Part&nbsp;I, Item&nbsp;1A of our Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2017, under the caption "Risk Factors" in Part&nbsp;II, Item&nbsp;1A of our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended
March&nbsp;31, 2018 and June&nbsp;30, 2018, and in Exhibit&nbsp;99.2 to our Current Report on Form&nbsp;8-K filed on August&nbsp;24, 2018, along with our consolidated financial statements
and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca75801_ptc_therapeutics,_inc."> </A>
<A NAME="toc_ca75801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PTC Therapeutics,&nbsp;Inc.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated
medicines that provide benefits to patients with rare disorders. We have launched two rare disease products and have a global commercial footprint. Our recent ability to commercialize products is the
foundation that drives our continued investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical
need. Our strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage our global commercial infrastructure to maximize
value for our patients and other stakeholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have two products, Translarna&#153; (ataluren) and Emflaza&#153; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening
disorder. Translarna is currently available for the treatment of nonsense mutation DMD in over 25 countries on a commercial basis or through a reimbursed early access program, or EAP program. We hold
worldwide commercialization rights to Translarna for all indications in all territories. Emflaza is approved in the United States for the treatment of DMD in patients five years and older. We also
have a spinal muscular atrophy (SMA) collaboration with F. Hoffman-La Roche&nbsp;Ltd and Hoffman-La Roche&nbsp;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy
Foundation, or SMA Foundation. Currently, our collaboration has three clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA
program. In August 2018, we acquired a pipeline of gene therapy product candidates through our acquisition of Agilis Biotherapeutics,&nbsp;Inc., or Agilis, and entered into a collaboration and
license agreement with Akcea Therapeutics,&nbsp;Inc., or Akcea, for the commercialization of TEGSEDI&#153; (inotersen) and WAYLIVRA&#153; (volanesorsen) for the treatment of rare
diseases in countries in Latin America and the Caribbean. In addition, we have a pipeline of product candidates that are in early
clinical and pre-clinical development. Our pre-clinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca75801_acquisition_of_agilis_biotherapeutics,_inc."> </A>
<A NAME="toc_ca75801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Acquisition of Agilis Biotherapeutics,&nbsp;Inc.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;23, 2018, we acquired Agilis, which prior to the acquisition was a privately-held biotechnology company advancing an innovative
gene therapy platform for rare monogenic diseases that affect the central nervous system, or CNS. Agilis's lead product candidate is GT-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase,
or AADC, deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The Agilis product candidate pipeline also includes a
gene therapy asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein.
Additionally, the Agilis pipeline includes two other gene therapy programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=737075,FOLIO='5',FILE='DISK108:[18ZCO1.18ZCO75801]CA75801A.;8',USER='CHE109871',CD='23-AUG-2018;17:49' -->
<A NAME="page_ca75801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>disorder
characterized by severe developmental delays. The acquisition was effected pursuant to an Agreement and Plan of Merger, dated as of July&nbsp;19, 2018, or the Merger Agreement, by and among
us, Agility Merger Sub,&nbsp;Inc., a Delaware corporation and our wholly owned, indirect subsidiary, Agilis, and, solely in its capacity as the representative, agent and attorney-in-fact of the
equityholders of Agilis, Shareholder Representative Services&nbsp;LLC, a Colorado limited liability company and resulted in Agilis becoming our wholly owned, indirect subsidiary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca75801_company_information"> </A>
<A NAME="toc_ca75801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Company Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated under the laws of the State of Delaware on March&nbsp;31, 1998, under the name PTC Therapeutics,&nbsp;Inc. Our
principal executive offices are located at 100 Corporate Court, South&nbsp;Plainfield, New Jersey 07080. Our telephone number is (908)&nbsp;222-7000. We maintain a website at </FONT> <FONT SIZE=2><I>www.ptcbio.com</I></FONT><FONT SIZE=2>. The
information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our
website address in this prospectus solely as an inactive textual reference. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=366871,FOLIO='6',FILE='DISK108:[18ZCO1.18ZCO75801]CA75801A.;8',USER='CHE109871',CD='23-AUG-2018;17:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc75801_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc75801_the_offering"> </A>
<A NAME="toc_cc75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Stock Offered by the Selling Stockholders</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3,500,907 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We will not receive any proceeds from the sale of shares in this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus for a discussion of factors to consider carefully before
deciding to purchase shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Select Market Symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PTCT</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=283440,FOLIO='7',FILE='DISK108:[18ZCO1.18ZCO75801]CC75801A.;5',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da75801_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da75801_risk_factors"> </A>
<A NAME="toc_da75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our common stock involves significant risks. In deciding whether to invest, and in consultation with your own financial and legal
advisors, you should carefully consider the risk factors and the risks described under the caption "Risk Factors" in Part&nbsp;I, Item&nbsp;1A of our Annual Report on Form&nbsp;10-K for the
fiscal year ended December&nbsp;31, 2017, under the caption "Risk Factors" in Part&nbsp;II, Item&nbsp;1A of our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended
March&nbsp;31, 2018 and June&nbsp;30, 2018, and in Exhibit&nbsp;99.2 to our Current Report on Form&nbsp;8-K filed on August&nbsp;24, 2018, as well as the other information contained in this
prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus. Any of these risks could have a material adverse effect on our business, financial condition,
results of operations and prospects and cause the value of our stock to decline, which could cause you to lose all or part of your investment. The risks and uncertainties we have described are not the
only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da75801_use_of_proceeds"> </A>
<A NAME="toc_da75801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not receive any proceeds from the sale of shares by the selling stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax, or legal services or any
other expenses incurred by the selling stockholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this
prospectus, including, without limitation, all registration and filing fees, Nasdaq Global Select Market listing fees, and fees and expenses of our counsel and our accountants. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da75801_selling_stockholders"> </A>
<A NAME="toc_da75801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the resale of shares of our common stock held by the selling stockholders listed in the table below. The selling
stockholders acquired these shares from us in a private offering pursuant to an exemption from registration afforded by Section&nbsp;4(a)(2) of the Securities Act and/or Regulation&nbsp;D
promulgated thereunder as partial consideration for our acquisition of Agilis on August&nbsp;23, 2018. Under the Merger Agreement, we agreed to file&nbsp;a registration statement on
Form&nbsp;S-3 with the SEC for the purposes of registering for resale the shares of our common stock issued to the selling stockholders and to maintain the effectiveness of the registration
statement until the six month anniversary date of the closing of the acquisition or such earlier time as all shares of common stock covered by the registration statement have been sold, subject to
certain exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth, to our knowledge, certain information about the selling stockholders as of August&nbsp;23, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our
knowledge, all persons named in the table have sole voting and investment power with respect to their shares of common stock, except to the extent authority is shared by spouses under applicable law.
The inclusion of any shares in this table does not constitute an admission of beneficial ownership for the person named below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=342076,FOLIO='8',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<A NAME="page_da75801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Common<BR>
Stock Beneficially<BR>
Owned Prior<BR>
to Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Common<BR>
Stock to be<BR>
Beneficially Owned<BR>
After Offering(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
of Common Stock<BR>
Being Offered </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Selling Stockholder

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>1307&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>58,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>58,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Abraxus Trust</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>46,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>46,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adam Gray and Kerri Miller</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adam L. Gray Revocable Trust&nbsp;U/A/D&nbsp;10/5/2006</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Allen Adler</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Barton Children Trust</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>22,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>22,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Joseph U. Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>190,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Kathleen Wagner Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,877</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,877</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Lila Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Linda Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Maggie Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Scott Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Barton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>213,322</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(14)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>BGR Capital,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(15)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21,473</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>BioMatrix Partners,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>401,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(16)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>401,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Carruthers Family Trust&nbsp;UA&nbsp;4/1/04</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(17)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>James J. Collins</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(18)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anne Marie Conway#+</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(19)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jodi Ann Cook#+</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(20)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cure FA Foundation</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(21)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Gold Bench Capital,&nbsp;LLC</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>233,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(22)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>233,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Christopher Guttilla</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,233</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(23)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,233</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Benjamin Hough</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>53,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(24)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>53,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Michael R. Hough</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>64,032</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(25)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>64,032</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Howard Klion</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,820</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(26)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,820</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Paolo Leone</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(27)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Level One Partners,&nbsp;LLC</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>604,345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(28)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.2%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>604,345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas McGahren</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(29)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,697</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Mark Merrill</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(30)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>NRM VII Holdings I,&nbsp;LLC</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>137,551</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(31)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>137,551</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Kevin O'Brien#+</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>572</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(32)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>572</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Robert William Postma</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>313,742</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(33)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>313,742</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Mark J. Pykett#+</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,209</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(34)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,209</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Gregory Scott Robinson</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,254</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(35)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,254</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Brett Ryan</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(36)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sands Capital Private Growth Fund II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>604,345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(37)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.2%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>604,345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William P. Saunders</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(38)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chris Shackelton</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(39)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Bradley Christopher Shoup</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(40)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adrian Stecyk</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(41)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chrystyna Bedrij Stecyk</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(42)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,155</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Richard Thorn</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>477</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(43)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>477</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Storey Revocable Trust</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,683</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(44)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,683</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Arthur Tzianabos</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(45)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Hans Utsch</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>143,108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(46)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>143,108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>White Rock Capital Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>179,222</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(47)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>179,222</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Patricia Williams</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(48)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Mark Zizzamia</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(49)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Additional selling stockholders as a group (4&nbsp;persons)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,975</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(50)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,975</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Less
than 1%.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>#</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Employee
or former employee of us or Agilis.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Received
an inducement grant for non-statutory stock options from us pursuant to the Nasdaq inducement grant exception on August&nbsp;23, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
do not know when or in what amounts a selling stockholder may offer shares for sale. The selling stockholders might not sell any or all of the shares offered by
this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or understandings with
respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this
table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=837814,FOLIO='9',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<A NAME="page_da75801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 58,100 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Cabana Management,&nbsp;LLC is
general partner and Casey McManemin is manager of the selling stockholder. Voting and investment control over the shares is held by Casey McManemin, manager of the selling stockholder. The address of
the selling stockholder is 3838 Oak Lawn Ave. Suite 425, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 46,480 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by John D. Harkey, Jr., sole trustee. The address of the selling stockholder is 12200 Stemmons Frwy, Suite&nbsp;100, Dallas, TX 75234.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 2,385 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 4,770 shares of common stock
issued to Adam L. Gray Revocable Trust U/A/D 10/5/2006 pursuant to the Merger Agreement and registered hereby, over which shares Mr.&nbsp;Gray has investment and voting control and of which entity
Mr.&nbsp;Gray is trustee. The address of the selling stockholder is 4 Fairgreen Ave., Old Greenwich, CT&nbsp;06870.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 4,770 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control over
the shares is held by Adam Gray, trustee. The address of the selling stockholder is 4 Fairgreen Ave., Old Greenwich, CT&nbsp;06870.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 68,775 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 800 Park Ave., New York, NY 10021.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 22,734 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by Thomas Barton, trustee. The address of the selling stockholder is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 179,222 shares of common stock
issued to White Rock Capital Partners,&nbsp;L.P. pursuant to the Merger Agreement and registered hereby, over which shares the selling stockholder has shared investment and voting control. The
address of the selling stockholder is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 6,877 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 10026 Calvin Run Rd., Great Falls, VA 22066.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 4340 Overhill Dr., Dallas, TX 75205.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 4340 Overhill Dr., Dallas, TX 75205.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 4340 Overhill Dr., Dallas, TX 75205.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The selling stockholder may be
deemed to be an affiliate of National Securities Corp., a registered broker-dealer. The selling stockholder represented that he acquired the shares in the ordinary course of business and, at the time
of the acquisition of the shares, had no agreements or understandings, directly or indirectly, with any person to distribute the shares. The address of the selling stockholder is 4340 Overhill Dr.,
Dallas, TX&nbsp;75205.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 11,366 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby, 179,222 shares of common stock
issued to White Rock Capital Partners,&nbsp;L.P. pursuant to the Merger Agreement and registered hereby, over which shares the selling stockholder has shared investment and voting control, and
22,734 shares of common stock issued to the Barton Children Trust pursuant to the Merger Agreement and registered hereby, over which shares the selling stockholder has investment and voting control.
The address of the selling stockholder is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 21,473 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 9,286 shares of common stock
issued to Brett Ryan pursuant to the Merger Agreement and registered hereby. Voting and investment control over the shares is held by Brett Ryan, the manager of the selling stockholder. The address of
the selling stockholder is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 401,158 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Investment and voting control
over the shares is held by G. Houston Hall. Mr.&nbsp;Hall, the general partner of the selling stockholder, is a former member of the board of directors of Agilis. The address of the selling
stockholder is 5956 Sherry Ln., Suite&nbsp;1810, Dallas, TX 75225.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(17)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 30,122 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by James L. Carruthers and Noreen N. Carruthers. The address of the selling stockholder is 68&nbsp;Inglewood Ln., Atherton, CA 94027.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(18)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 2,495 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 118 Glen Ave., Newton, MA 02459.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(19)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 4,770 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 370 South Main St., Mansfield, MA 02048. The selling </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=620663,FOLIO='10',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<A NAME="page_da75801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>stockholder
served as Vice President of Clinical Operations of Agilis prior to the acquisition and currently serves as our Clinical Head of Biologics.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(20)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 17,175 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 126 Hillborn Dr., Newtown, PA 18940. The selling stockholder served as Chief Operating Officer of Agilis prior to the acquisition and currently serves as our Head of Gene Therapy
Strategy.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(21)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 95,405 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Investment and voting control
over the shares is held by Thomas Hamilton. The address of the selling stockholder is 211 Stuyvesant Ave., Rye, NY 10580.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(22)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 233,593 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Investment and voting control
over the shares is held by Alexander M. Seaver and Bradley R. Kent. Mr.&nbsp;Seaver, a member of the selling stockholder, is a former member of the board of directors of Agilis. The address of the
selling stockholder is 199&nbsp;Elm St., New&nbsp;Canaan, CT&nbsp;06840.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(23)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 51,233 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The selling stockholder may be
deemed to be an affiliate of Raymond James, a registered broker-dealer. The selling stockholder represented that he acquired the shares in the ordinary course of business and, at the time of the
acquisition of the shares, had no agreements or understandings, directly or indirectly, with any person to distribute the shares. The address of the selling stockholder is 57 Colt Rd., Summit, NJ
07901.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(24)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 53,248 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 2756 Windsor Rd., Winston-Salem, NC 27104.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(25)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 64,032 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 2809 Lazy Ln., Winston-Salem, NC 27106.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(26)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 6,820 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 5927 Joyce Way, Dallas, TX 75225.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(27)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 2,495 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 312 Cotswold Ln., Cherry Hill, NJ 08034.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(28)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 604,345 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by Robert D. Hardie and Molly G. Hardie, the partners of the selling stockholder. The address of the selling stockholder is 2105 Dogwood Ln., Charlottesville, VA&nbsp;22901.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(29)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 28,697 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 349 11<SUP>th</SUP>&nbsp;St., Brooklyn, NY 11215. The selling stockholder is a former member of the Agilis Scientific Advisory Board and a member of Agilis's founding group.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(30)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 17,077 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 50&nbsp;Murray St., Apt.&nbsp;711, New York, NY&nbsp;10007.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(31)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 137,551 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Investment and voting control
over the shares is held by Randal J. Kirk, the manager of Third Security,&nbsp;LLC, which is the manager of the selling stockholder. The address of the selling stockholder is c/o Third
Security,&nbsp;LLC, Attn: Legal Department, 1881 Grove Ave., Radford, VA 24141. An affiliate of the selling stockholder is party to an Exclusive Channel Collaboration Agreement with Agilis.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(32)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 572 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 149 Willow St., Acton, MA 10720. The selling stockholder served as Vice President of Finance of Agilis prior to the acquisition and currently serves as our Head of Finance Operations.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(33)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 313,742 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is P.O.&nbsp;Box&nbsp;2017, 141 Mecox Rd., Water Mill, NY 11976.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(34)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 56,209 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 223A Main St., Boxford, MA 01923. The selling stockholder served as President and Chief Executive Officer of Agilis prior to the acquisition and currently serves as our Chief Innovation
Officer.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(35)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 9,254 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 4 Foley Farm Rd., Wilmington, MA 01887.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(36)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 9,286 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 21,473 shares of common stock
issued to BGR Capital,&nbsp;L.P. pursuant to the Merger Agreement and registered hereby, over which the selling stockholder has investment and voting control. The address of the selling stockholder
is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(37)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 604,345 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is shared by Ian Ratcliffe and Frank M. Sands. </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=852201,FOLIO='11',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<A NAME="page_da75801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>Mr.&nbsp;Ratcliffe,
an officer of the selling stockholder, previously served as a member of the Agilis Board of Directors. The address of the selling stockholder is 1000 Wilson Blvd.,
Suite&nbsp;3000, Arlington, VA 22209.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(38)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 28,739 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 1700 Hardin Ln., Powell, OH 43065.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(39)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 9,540 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 487&nbsp;West Rd., New&nbsp;Canaan, CT&nbsp;06840.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(40)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 2,385 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 6337 Northport Dr., Dallas, TX 75230.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(41)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 17,077 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 34,155 shares of common stock
issued to Chrystyna Bedrij Stecyk, the spouse of the selling stockholder, pursuant to the Merger Agreement and registered hereby with respect to which the selling stockholder may have a beneficial
ownership interest. The address of the selling stockholder is 21 S. End Ave. #603, New York, NY 10280. The selling stockholder served as a member of the Board of Directors of Agilis prior to the
acquisition.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(42)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 34,155 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby and 17,077 shares of common stock
issued to Adrian Stecyk, the spouse of the selling stockholder, pursuant to the Merger Agreement and registered hereby, with respect to which the selling stockholder may have a beneficial ownership
interest. The address of the selling stockholder is 21 S. End Ave. #603, New York, NY 10280.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(43)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 477 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 20 Dudley Rd., Mendon, MA 01756.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(44)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 5,683 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by Paula Kay White Storey and Reggie Louis Storey. The address of the selling stockholder is 508 Las Lomas Dr., Heath, TX 75032.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(45)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 3,303 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 114 Duck Rd., Reading, MA 01867.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(46)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 143,108 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 15 Legare St., Charleston, SC 29401.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(47)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 179,222 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Voting and investment control
over the shares is held by Thomas Barton and Joseph Barton. The address of the selling stockholder is 3131 Turtle Creek Blvd., Suite&nbsp;800, Dallas, TX 75219.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(48)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 752 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 3470 Pin Oak Ct., Catharpin, VA 20143.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(49)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 17,077 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholder is 400 Chambers St., Apt. 25K, New York, NY 10282.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(50)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 15,975 shares of common stock issued to the selling stockholders pursuant to the Merger Agreement and registered hereby. The address of the selling
stockholders is c/o Shareholder Representative Services&nbsp;LLC, 950 17th&nbsp;St., Suite&nbsp;1400, Denver, CO 80202. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Relationships with Selling Stockholders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the selling stockholders has had a material relationship with us or any of our subsidiaries within the past three years except as set
forth below or in the table above or the notes thereto. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the selling stockholders has held any position or office with us or any of our subsidiaries within the past three years, except that the selling stockholders indicated below or
in the table above or the notes thereto have been employed by us and/or Agilis. In connection with our acquisition of Agilis, we entered into employment agreements with Jodi Ann Cook, formerly Chief
Operating Officer of Agilis, to serve as our Head of Gene Therapy Strategy, and Mark Pykett, formerly Chief Executive Officer of Agilis, to serve as our Chief Innovation Officer. Under her employment
agreement, Ms.&nbsp;Cook will receive an annual base salary and will be eligible to receive an annual bonus and equity grant beginning in 2019. Pursuant to her employment agreement, Ms.&nbsp;Cook
also received an inducement grant for non-statutory stock options pursuant to the Nasdaq inducement grant exception for options to purchase 75,000 shares of our common stock on the closing date of our
acquisition of Agilis and in 2019 will receive a stock option grant for 50,000 shares of our common stock as her annual equity grant. Under his employment agreement, Mr.&nbsp;Pykett will receive an
annual base salary </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=15,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=895060,FOLIO='12',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<A NAME="page_da75801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
will be eligible to receive an annual bonus and equity grant beginning in 2019. Pursuant to his employment agreement, Mr.&nbsp;Pykett also received an inducement grant for non-statutory stock
options pursuant to the Nasdaq inducement grant exception for options to purchase 100,000 shares of our common stock on the closing date of our acquisition of Agilis and in 2019 will receive a stock
option grant for 50,000 shares of our common stock as his annual equity grant. In addition, we entered into employment agreements with Anne Marie Conway, formerly Vice President of Clinical Operations
of Agilis, to serve as our Clinical Head of Biologics, and Kevin O'Brien, formerly Vice President of Finance of Agilis, to serve as our Head of Finance Operations, that provide for a base salary and
the eligibility to receive an annual cash bonus and annual equity grant commensurate with and on the same terms as other comparable employees and pursuant to which Ms.&nbsp;Conway and
Mr.&nbsp;O'Brien each received an inducement grant for non-statutory stock options pursuant to the Nasdaq inducement grant exception for options to purchase in the aggregate amount 50,000 shares of
our common stock on the closing date of the acquisition. The employment agreements with Ms.&nbsp;Cook, Mr.&nbsp;Pykett, Ms.&nbsp;Conway and Mr.&nbsp;O'Brien also include certain other
customary terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the shares of common stock being registered hereby, each of the selling stockholders received its pro rata portion of the cash consideration in connection with the closing
of the acquisition.
Under the Merger Agreement, each selling stockholder will also be entitled to receive its pro rata portion of contingent payments from the Company based on (i)&nbsp;the achievement of certain
development milestones, (ii)&nbsp;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher, (iii)&nbsp;the
achievement of certain net sales, and (iv)&nbsp;a percentage of annual net sales for Friedreich ataxia and Angelman Syndrome during specified terms, and we are required to pay certain of the
development milestone payments regardless of whether the applicable milestones have been achieved. See the discussion under the heading "Merger Agreement" in our Current Report on Form&nbsp;8-K
filed with the SEC on July&nbsp;19, 2018 for more details with respect to the consideration, including contingent consideration, that has been paid or may become payable to selling stockholders in
connection with the acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Merger Agreement, we will indemnify each selling stockholder against any damages to which a selling stockholder may become subject by reason of any material misstatement or
omission in this registration statement, except to the extent that such damages arise out of or are based upon information furnished to us by or on behalf of Agilis or an Agilis equityholder for use
in this registration statement. Each selling stockholder will indemnify us and certain related persons against any damages to which such indemnified parties may become subject by reason of any
material misstatement or omission in this registration statement or any violation or alleged violation of the Securities Act, the Exchange Act, or any state securities law, or any rule promulgated
under any of the foregoing, in each case to the extent based upon any action or omission made in reliance upon information provided by such selling stockholder for use in this registration statement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the terms of the Merger Agreement, included as Exhibit&nbsp;2.1
hereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=16,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=820563,FOLIO='13',FILE='DISK108:[18ZCO1.18ZCO75801]DA75801A.;23',USER='CHE107256',CD='24-AUG-2018;06:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc75801_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_description_of_capital_stock"> </A>
<A NAME="toc_dc75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description of our capital stock is intended as a summary only. This description is based upon, and is qualified by reference to,
our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of Delaware corporate law. This summary is not complete. You should read our restated certificate
of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus forms&nbsp;a part, for the provisions that are important to you. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
authorized capital stock consists of 125,000,000 shares of common stock and 5,000,000 shares of preferred stock. As of August&nbsp;23, 2018, there were 50,265,287 shares of common
stock outstanding and no shares of preferred stock outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of
stockholders and do not
have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. In general,
except (1)&nbsp;for the election of directors, (2)&nbsp;as described below under "&#151;Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have
Anti-Takeover Effects&#151;Super-Majority Voting," (3)&nbsp;in the future to the extent that we have two or more classes or series of stock outstanding with separate voting rights and
(4)&nbsp;as otherwise required by law, any matter to be voted on by our stockholders at any meeting is decided by the vote of the holders of a majority in voting power of the votes cast by the
holders of shares of our stock present or represented at the meeting and voting affirmatively or negatively on such matter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors,
subject to any
preferential dividend rights of outstanding preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation and Dissolution.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive
proportionately
all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences
and privileges
of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Agent and Registrar.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC is the transfer agent and registrar for our
common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nasdaq Global Select Market.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on The Nasdaq Global Select Market under the symbol "PTCT." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more
series without stockholder approval, subject to any limitations imposed by the Nasdaq Marketplace Rules. Our board of directors has the discretion to determine the rights, preferences, privileges and
restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of
directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=17,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=135484,FOLIO='14',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stock,
while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to
acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Currently, we have no shares of preferred stock outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options and Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2018, we had issued and outstanding options to purchase 8,166,403 shares of our common stock at a weighted average
exercise price of $27.06 per share and warrants to purchase (i)&nbsp;7,030 shares of our common stock at an exercise price of $128.00 per share and (ii)&nbsp;130 shares of our common stock at an
exercise price of $2,520.00 per share. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Convertible Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2015, we issued, at par value, $150.0&nbsp;million aggregate principal amount of 3.0% convertible senior notes due 2022, or
Convertible Notes. The Convertible Notes bear cash interest at a rate of 3.0% per year, payable semi-annually on February&nbsp;15 and August&nbsp;15 of each year, beginning on February&nbsp;15,
2016. The Convertible Notes will mature on August&nbsp;15, 2022, unless earlier repurchased or converted. The conversion rate for the Convertible Notes was initially, and remains, 17.7487 shares of
our common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $56.34 per share of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Effects of Authorized but Unissued Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations
imposed by the listing standards of the Nasdaq Global Select Market. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise
additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our
board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire,
or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest or otherwise. In addition, if we issue preferred
stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover
Effects  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are subject to Section&nbsp;203 of the Delaware General Corporation Law. Subject to certain exceptions,
Section&nbsp;203
prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following the date that the person became an interested
stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders
in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A "business combination"
includes, among other things, a merger or consolidation involving us and the "interested stockholder" and the sale of more than 10% of our assets. In general, an "interested stockholder" is any entity
or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in
Section&nbsp;203 are not applicable to any of our existing stockholders that owned 15% or more of our outstanding voting stock upon the closing of our initial public offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=18,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=316919,FOLIO='15',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Staggered Board; Removal of Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation and our bylaws divide our board of directors into three classes
with
staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of 75% of
our shares of capital stock present in person or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including a vacancy resulting
from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our certificate of incorporation provides that the authorized
number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove
directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our
company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate
of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is
properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by
law, special meetings of the stockholders can only be called by our chairman of the board, our president or chief executive officer or our board of directors. In addition, our bylaws establish an
advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors.
Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a
stockholder of record on the record date for the meeting, who is entitled to vote at the meeting
and who has delivered timely written notice in proper form to our secretary of the stockholder's intention to bring such business before the meeting. These provisions could have the effect of delaying
until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from
making a tender offer for our common stock, because even if it acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or
approving a merger, only at a duly called stockholders meeting and not by written consent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-Majority Voting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares
entitled to vote
on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or bylaws, as the case may be, requires a greater
percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be
entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election
of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Liability  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the
Delaware General Corporation Law and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director.
However, these provisions do not eliminate or limit the liability of any of our directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any breach of the director's duty of loyalty to us or our stockholders; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=19,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=466088,FOLIO='16',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such
amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our
directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our certificate of incorporation provides that we must indemnify our directors and officers and we must advance expenses, including attorneys' fees, to our directors and
officers in connection with legal proceedings, subject to very limited exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. In addition, we have entered into indemnification agreements with our directors. These indemnification agreements may require us, among other things, to indemnify each such
director for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as one of our directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as
members of our board of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_plan_of_distribution"> </A>
<A NAME="toc_dc75801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares covered by this prospectus may be offered and sold from time to time by the selling stockholders. The term "selling stockholders"
includes donees, pledgees, assignees, transferees or other successors-in-interest selling shares received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other non-sale related transfer. The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be
made on one or more exchanges in any market or trading facility on which the shares are traded, or in the over-the-counter market or otherwise, at fixed prices, at prices and under terms then
prevailing or at prices related to the then current market price or in negotiated transactions. The selling stockholders may sell their shares by one or more of, or a combination of, the following
methods:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ordinary brokerage transactions and transactions in which the broker solicits purchasers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block
as principal to facilitate the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an over-the-counter distribution in accordance with the rules of the Nasdaq Global Select Market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through one or more underwritten offerings on a firm commitment or best efforts basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in privately negotiated transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in options transactions. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=20,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=694702,FOLIO='17',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, any shares that qualify for sale pursuant to Rule&nbsp;144 may be sold under Rule&nbsp;144 rather than pursuant to this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the shares or
otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial
institutions may engage in short sales of the common stock in the course of hedging the positions they assume with selling stockholders. The selling stockholders may also sell the common stock short
and redeliver the shares to close out such short positions. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions which require
the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). The selling stockholders may also pledge or grant a security interest in shares to a broker-dealer, other financial institution or
other person, and, upon a default such pledgee or secured parties may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
effecting sales, broker-dealers or agents engaged by the selling stockholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions,
discounts or concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale. Except as set forth in this prospectus under the heading "Selling Stockholders," each
selling stockholder has informed us that it is not a registered broker-dealer or an affiliate of a registered broker-dealer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
offering the shares covered by this prospectus, the selling stockholders and any broker-dealers who execute sales for the selling stockholders may be deemed to be "underwriters"
within the meaning of the Securities Act in connection with such sales. Any profits realized by the selling stockholders and the
compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Any selling stockholder who is an "underwriter" within the meaning of the Securities Act will be subject
to the prospectus delivery requirements of the Securities Act and the provisions of the Exchange Act and the rules thereunder relating to stock manipulation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to comply with the securities laws of certain states, if applicable, the shares must be sold in such jurisdictions only through registered or licensed brokers or dealers. In
addition, in certain states the shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have advised the selling stockholders that the anti-manipulation rules of Regulation&nbsp;M under the Exchange Act may apply to sales of shares in the market and to the activities
of the selling stockholders and their affiliates. In addition, we will make copies of this prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery
requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including
liabilities arising under the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the time a particular offer of shares is made, if required, a prospectus supplement will be distributed that will set forth the number of shares being offered and the terms of the
offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount,
commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the selling stockholders against certain liabilities, including certain liabilities under the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=21,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=636992,FOLIO='18',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed with the selling stockholders to keep the Registration Statement of which this prospectus constitutes a part effective until the earlier of (i)&nbsp;such time as all of
the shares covered by this prospectus have been disposed of pursuant to and in accordance with the Registration Statement or (ii)&nbsp;February&nbsp;23, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_legal_matters"> </A>
<A NAME="toc_dc75801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares offered by this prospectus has been passed upon by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_experts"> </A>
<A NAME="toc_dc75801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth
in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on
Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements of the Emflaza Business as of and for the years ended December&nbsp;31, 2016 and 2015, incorporated in this prospectus by reference from the Current Report on
Form&nbsp;8-K/A dated July&nbsp;3, 2017 of PTC Therapeutics,&nbsp;Inc., have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, independent auditors, as stated in their report (which report
expresses an unmodified opinion and includes an emphasis-of-matter paragraph relating to the allocation of certain assets, liabilities, expenses, and income that have historically been held at the
Marathon Pharmaceutical Holdings,&nbsp;LLC corporate level but which are specifically identifiable or attributable to the Emflaza Business), which is incorporated herein by reference. Such financial
statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements of Agilis as of and for the years ended December&nbsp;31, 2017 and 2016, incorporated in this prospectus by reference from our Current Report on
Form&nbsp;8-K filed August&nbsp;24, 2018 have been audited by BDO USA,&nbsp;LLP, independent auditors, as stated in their report, which is incorporated herein by reference. Such financial
statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_where_you_can_find_more_information"> </A>
<A NAME="toc_dc75801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.ptcbio.com. Our website is not a
part of this prospectus and is not incorporated by reference in this prospectus. You may also read and copy any document we file at the SEC's Public Reference Room, 100&nbsp;F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and
regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities we are offering. Statements
in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by
reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC at the address listed above or from
the SEC's website. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=22,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=995772,FOLIO='19',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<A NAME="page_dc75801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc75801_incorporation_by_reference"> </A>
<A NAME="toc_dc75801_6"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose
important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus.
Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or
incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document
previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No.&nbsp;001-35969) and any future filings we make
with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those
documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or
completed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017, including the information specifically incorporated by
reference into the Annual Report on Form&nbsp;10-K from our definitive proxy statement for the 2018 Annual Meeting of Stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2018 and June&nbsp;30, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Current Reports on Form&nbsp;8-K filed on April&nbsp;20, 2017 (solely with respect to Items&nbsp;2.01, 3.02 and 9.01, as amended on
July&nbsp;3, 2017), February&nbsp;20, 2018, April&nbsp;3, 2018, June&nbsp;14, 2018, July&nbsp;19, 2018 (solely with respect to Items&nbsp;1.01, 3.02 and 9.01), August&nbsp;2, 2018
(solely with respect to Item&nbsp;1.01) and August&nbsp;24, 2018 (solely with respect to Items&nbsp;1.01, 2.01, 3.02, 8.01 and 9.01); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of the securities contained in our registration statement on Form&nbsp;8-A filed under the Exchange Act on June&nbsp;14,
2013, including any amendment or report filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or superceded for purposes of this prospectus to the extent that a
statement contained in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in this prospectus modifies or replaces such statement. Any
statements so modified or superceded shall not be deemed, except as so modified or superceded, to constitute a part of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>PTC
Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080<BR>
(908)&nbsp;222-7000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=23,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=354394,FOLIO='20',FILE='DISK108:[18ZCO1.18ZCO75801]DC75801A.;7',USER='CHE107256',CD='24-AUG-2018;06:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>PTC THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>August&nbsp;24, 2018  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=656879,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]HO75801A.;3',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja75801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja75801_part_ii._information_not_required_in_prospectus"> </A>
<A NAME="toc_ja75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II.<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja75801_item_14._other_expense__ja701995"> </A>
<A NAME="toc_ja75801_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being
registered hereby, all of which will be borne by the Registrant (except any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or
legal services or any other expenses incurred by the
selling stockholders in disposing of the shares). All amounts shown are estimates except the SEC registration fee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,908</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>134,908 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja75801_item_15._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja75801_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors or its
stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The
Registrant's certificate of incorporation provides that no director shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director,
notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for
breaches of fiduciary duty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145
of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain
other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in
a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her
conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such
person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of
liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnify for such expenses which the Court of Chancery or such other court shall deem
proper. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant's certificate of incorporation provides that it will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed
action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to
become, the Registrant's director or officer, or is or was serving, or has agreed to serve, at the Registrant's request as a director, officer, partner, employee or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=244218,FOLIO='II-1',FILE='DISK108:[18ZCO1.18ZCO75801]JA75801A.;18',USER='CHE107256',CD='24-AUG-2018;06:28' -->
<A NAME="page_ja75801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reason
of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to,
the Registrant's best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant's certificate of incorporation also provides that the Registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the
Registrant to procure a judgment in its favor by reason of the fact that the Indemnitee is or was, or has agreed to become, the Registrant's director or officer, or is or was serving, or has agreed to
serve, at the Registrant's request as a director, officer, partner, employee or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise,
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement
actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be
in, or not opposed to, the Registrant's best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys' fees)
actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the Registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain
circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant has entered into indemnification agreements with its directors and executive officers. In general, these agreements provide that the Registrant will indemnify the director
or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of the Registrant or in connection with their service at the Registrant's
request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for
indemnification and establish certain presumptions that are favorable to the director or executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant maintains a general liability insurance policy which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their
capacities as directors or officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriting agreement Registrant enters into in connection with an offering of common stock being registered under this registration statement may provide that the underwriters will
indemnify,
under certain conditions, Registrant and Registrant's directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=838383,FOLIO='II-2',FILE='DISK108:[18ZCO1.18ZCO75801]JA75801A.;18',USER='CHE107256',CD='24-AUG-2018;06:28' -->
<A NAME="page_ja75801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja75801_item_16._exhibits."> </A>
<A NAME="toc_ja75801_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000110465918046031/a18-17399_1ex2d1.htm">Agreement and Plan of Merger, dated July&nbsp;19, 2018, by and among PTC Therapeutics,&nbsp;Inc., Agility Merger Sub,
&nbsp;Inc., Agilis Biotherapeutics,&nbsp;Inc. and, solely in its capacity as equityholder representative, Shareholder Representative Services&nbsp;LLC (incorporated by reference to Exhibit&nbsp;2.1 to the Current Report on Form&nbsp;8-K filed by the
Registrant on July&nbsp;19, 2018)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000104746913006241/a2215112zex-3_3.htm">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit&nbsp;3.3 to the
Registration Statement on Form&nbsp;S-1, as amended (File No.&nbsp;333-188657), of the Registrant)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000074/bylawsexhibit31of421178-k.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit&nbsp;3.1 to the Current
Report on Form&nbsp;8-K filed by the Registrant on April&nbsp;21, 2017)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236544zex-5_1.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236544zex-23_1.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm for the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236544zex-23_2.htm">Consent of Deloitte&nbsp;&amp; Touche&nbsp;LLP</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236544zex-23_3.htm">Consent of BDO USA,&nbsp;LLP</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236544zex-5_1.htm">Consent of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP (included in Exhibit&nbsp;5.1)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="#sig">Powers of Attorney (included on the signature page to the Registration Statement)</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Confidential
treatment has been requested for certain portions that are omitted from this exhibit. The omitted information has been filed separately with
the SEC pursuant to the registrant's application for confidential treatment. In addition, schedules have been omitted from this exhibit pursuant to Item&nbsp;601(b)(2) of Regulation&nbsp;S-K. A
copy of any omitted schedule will be furnished supplementally to the SEC upon request; provided, however, that the registrant may request confidential treatment for any document so furnished. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja75801_item_17._undertakings."> </A>
<A NAME="toc_ja75801_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20&nbsp;percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=948683,FOLIO='II-3',FILE='DISK108:[18ZCO1.18ZCO75801]JA75801A.;18',USER='CHE107256',CD='24-AUG-2018;06:28' -->
<A NAME="page_ja75801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such
information in this registration statement; </FONT></DD></DL>
</UL>
</UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that paragraphs&nbsp;(1)(i), (1)(ii) and (1)(iii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are incorporated by reference in this registration statement, or is contained in
a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of this registration statement. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2> offering
thereof.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for the purpose of determining liability under the Securities Act to any purchaser:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>each
prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>each
prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B
relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall
be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that
time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2> offering thereof. </FONT><FONT SIZE=2><I>Provided, however</I></FONT><FONT SIZE=2> , that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference in the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section&nbsp;13(a) or 15(d) of
the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in this
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT> <FONT SIZE=2><I>bona fide</I></FONT><FONT
SIZE=2> offering thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act
and is, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=687207,FOLIO='II-4',FILE='DISK108:[18ZCO1.18ZCO75801]JA75801A.;18',USER='CHE107256',CD='24-AUG-2018;06:28' -->
<A NAME="page_ja75801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=578633,FOLIO='II-5',FILE='DISK108:[18ZCO1.18ZCO75801]JA75801A.;18',USER='CHE107256',CD='24-AUG-2018;06:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc75801_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="sig"></A>SIGNATURES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form&nbsp;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough
of South Plainfield, State of New Jersey, on this 24<SUP>th</SUP>&nbsp;day of August, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>PTC THERAPEUTICS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;STUART W. PELTZ, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Stuart W. Peltz, Ph.D.<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc75801_power_of_attorney_and_signatures"> </A>
<A NAME="toc_jc75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  POWER OF ATTORNEY AND SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, the undersigned officers and directors of PTC Therapeutics,&nbsp;Inc., hereby severally constitute and appoint Stuart W. Peltz, Christine
Utter and Mark E. Boulding, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities
indicated below the Registration Statement on Form&nbsp;S-3 filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and to file or cause to be
filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on our behalf in
our capacities as officers and directors to enable PTC Therapeutics,&nbsp;Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and
Exchange Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;STUART W. PELTZ, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Stuart W. Peltz, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;CHRISTINE UTTER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christine Utter</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Principal Financial Officer (Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL SCHMERTZLER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Schmertzler</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DAWN SVORONOS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dawn Svoronos</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=226254,FOLIO='II-5',FILE='DISK108:[18ZCO1.18ZCO75801]JC75801A.;8',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<A NAME="page_jc75801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg75801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;ALLAN JACOBSON, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Allan Jacobson, Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;GLENN D. STEELE, JR., M.D., PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Glenn D. Steele, Jr., M.D., Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DAVID P. SOUTHWELL<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David P. Southwell</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JEROME B. ZELDIS, M.D., PH.D.<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jerome B. Zeldis, M.D., Ph.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>August&nbsp;24, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=612791,FOLIO='II-6',FILE='DISK108:[18ZCO1.18ZCO75801]JC75801A.;8',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>a2236544zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZCO75801_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg75801_exhibit_5.1"> </A>
<A NAME="toc_kg75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;5.1    <BR>    </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g447809.jpg" ALT="GRAPHIC" WIDTH="132" HEIGHT="123">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>August&nbsp;24,
2018 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PTC
Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Re:
Registration Statement on Form&nbsp;S-3 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Ladies
and Gentlemen: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
opinion is furnished to you in connection with a Registration Statement on Form&nbsp;S-3 (the "Registration Statement") filed by PTC Therapeutics,&nbsp;Inc., a Delaware
corporation (the "Company"), with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), for the registration for resale of an
aggregate of 3,500,907 shares of common stock, par value $0.001 per share (the "Shares"), of the Company. All of the Shares are being registered on behalf of certain stockholders of the Company (the
"Selling Stockholders"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are acting as counsel for the Company in connection with the registration for resale of the Shares. We have examined and relied upon signed copies of the Registration Statement as
filed with the Commission, including the exhibits thereto. We have also examined and relied upon the Certificate of Incorporation of the Company (as amended or restated from time to time, the
"Certificate of Incorporation"), the Bylaws of the Company (as amended or restated from time to time, the "Bylaws") and minutes of meetings of the stockholders and the Board of Directors of the
Company as provided to us by the Company, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to
original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
opinion below, insofar as it relates to the Shares being fully paid, is based solely on a certificate of the Principal Financial Officer of the Company confirming the Company's
receipt of the consideration called for by the applicable resolutions authorizing the issuance of such Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
assume that the appropriate action will be taken, prior to the offer and sale of the Shares, to register and qualify the Shares for sale under all applicable state securities or "blue
sky" laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and are validly issued, fully paid and nonassessable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g586184.jpg" ALT="GRAPHIC" WIDTH="634" HEIGHT="30">
  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="2",CHK=883352,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]KG75801A.;21',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<A NAME="page_kg75801_1_2"> </A>
<BR>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently
existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments
which might affect any matters or opinions set forth herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5) of
Regulation&nbsp;S-K under the Securities Act and to the use of our name therein and in the related prospectus under the caption "Legal Matters." In giving such consent, we do not hereby admit that
we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>Very truly yours,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
WILMER CUTLER PICKERING<BR>
HALE AND DORR&nbsp;LLP</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;BRIAN A. JOHNSON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Brian A. Johnson, a Partner</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="2",CHK=103887,FOLIO='2',FILE='DISK108:[18ZCO1.18ZCO75801]KG75801A.;21',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZCO75801_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg75801_1">Exhibit 5.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=JKEENE,SEQ=,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>a2236544zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZCO75801_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ki75801_exhibit_23.1"> </A>
<A NAME="toc_ki75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ki75801_consent_of_independent__ki702325"> </A>
<A NAME="toc_ki75801_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form&nbsp;S-3) and related Prospectus of
PTC Therapeutics,&nbsp;Inc. for the registration of common stock and to the incorporation by reference therein of our reports dated March&nbsp;6, 2018, with respect to the consolidated financial
statements of PTC Therapeutics,&nbsp;Inc. and the effectiveness of internal control over financial reporting of PTC Therapeutics,&nbsp;Inc. included in its Annual Report (Form&nbsp;10-K) for the
year ended December&nbsp;31, 2017, filed with the Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Iselin,
New Jersey<BR>
August&nbsp;24, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="3",CHK=709619,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]KI75801A.;3',USER='CHE106630',CD='22-AUG-2018;23:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZCO75801_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki75801_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki75801_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JKEENE,SEQ=,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>a2236544zex-23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZCO75801_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kk75801_exhibit_23.2"> </A>
<A NAME="toc_kk75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kk75801_consent_of_independent_auditors"> </A>
<A NAME="toc_kk75801_2"> </A></FONT> <FONT SIZE=2><B>  CONSENT OF INDEPENDENT AUDITORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the incorporation by reference in the Registration Statement on Form&nbsp;S-3 of PTC Therapeutics,&nbsp;Inc. of our report
dated May&nbsp;10, 2017, relating to the financial statements of the Emflaza Business as of and for the years ended December&nbsp;31, 2016 and 2015 (which report expresses an unmodified opinion
and includes an emphasis-of-matter paragraph relating to the allocation of certain assets, liabilities, expenses, and income that have historically been held at the Marathon Pharmaceutical
Holdings,&nbsp;LLC corporate level but which are specifically identifiable or attributable to the Emflaza Business), appearing in the Current Report on Form&nbsp;8-K/A dated July&nbsp;3, 2017 of
PTC Therapeutics,&nbsp;Inc., and to the reference to us under the heading "Experts" in the Prospectus, which is part of this Registration Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Deloitte&nbsp;&amp; Touche&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Chicago,
Illinois<BR>
August&nbsp;24, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="4",CHK=354306,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]KK75801A.;7',USER='CHE109873',CD='23-AUG-2018;15:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZCO75801_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk75801_1">Exhibit 23.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk75801_2">CONSENT OF INDEPENDENT AUDITORS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JKEENE,SEQ=,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>a2236544zex-23_3.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZCO75801_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="km75801_exhibit_23.3"> </A>
<A NAME="toc_km75801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.3    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="km75801_consent_of_independent__km702267"> </A>
<A NAME="toc_km75801_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Certified Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PTC
Therapeutics,&nbsp;Inc.<BR>
South Plainfield, New Jersey </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of PTC Therapeutics,&nbsp;Inc. of our report dated
August&nbsp;21, 2018, relating to the consolidated financial statements of Agilis Biotherapeutics,&nbsp;Inc. as of and for the years ended December&nbsp;31, 2017 and 2016 appearing in PTC
Therapeutics,&nbsp;Inc.'s Form&nbsp;8-K filed on August&nbsp;24, 2018. Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also consent to the reference to us under the caption "Experts" in the Prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
BDO USA,&nbsp;LLP<BR>
Boston, Massachusetts </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>August&nbsp;24,
2018 </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:times;"><FONT SIZE=1>BDO USA,&nbsp;LLP, a Delaware limited liability partnership, is the U.S.&nbsp;member of BDO International Limited, a UK company limited by guarantee, and
forms part of the international BDO network of independent member firms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>BDO is the brand name for the BDO network and for each of the BDO Member Firms.</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="5",CHK=592865,FOLIO='blank',FILE='DISK108:[18ZCO1.18ZCO75801]KM75801A.;5',USER='CHE109871',CD='23-AUG-2018;15:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZCO75801_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km75801_1">Exhibit 23.3</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km75801_2">Consent of Independent Certified Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JKEENE,SEQ=,EFW="2236544",CP="PTC THERAPEUTICS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g337856.jpg
<DESCRIPTION>G337856.JPG
<TEXT>
begin 644 g337856.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ Y35),3%]'4D%02$E#4SI;4%1#7U1(
M15)!4$555$E#4U])3D-=4%1#7U1(15)?2U],3T=/+D504__; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( %
MJ0,!(@ "$0$#$0'_Q  ?   !! (# 0$            +  <)"@$( P4& @3_
MQ !-$   !@(! @0# 0D,!0T    ! @,$!08'" D $0H2$R$4,5$5%CE!87%X
M@;&W&"(H,CA8<I&7H;+6%QHC)]$D,S='2%-55E=WE+/P_\0 %0$! 0
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M]ILW!7;*F[7X3IUCCK:Q8BFBX7KV38.)@INXPAC#Z2DW4,BR;8RYC>5\"X&
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M,QA';+6?,, \583&+\^8AO;%RBIZ1R*UF_P$H<@G[#V361;JH*^P]TE#E$!
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M[_A[]QZ(6^-)WOCXRCZ_<>-,G?-/6B70V,S4S8.6QO@ZK!EF*UB:N2Q2>JJ
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M2Q5QRZ]88S[CO'LSB3"MUQY:GLYAY.XSE4M4Y<Z\-BBXV?FX9PU2=I2$NO\
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966FO^[$G_@\M_P#$/_PZ)6/MLL]8\V?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g447809.jpg
<DESCRIPTION>G447809.JPG
<TEXT>
begin 644 g447809.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ \35),3%]'4D%02$E#4SI;4%1#7U1(
M15)!4$555$E#4U])3D-=5TE,34522$%,15]+7TQ44DA$+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_   L( 'L A $!$0#_Q  =  $  @,  P$
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M2H!?+#'LPJ8F)C0X2:_7&=BU7T+V# AMXB*SO*5!DZ1^,>2>CIS-N':LO<C
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M95..!V,GI9S,T(IQ_JK0O>JZ.5)/QCA [6G8BHT%O A=8(]C+"DRXZ;&+_\
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+)T[?EGND;,O?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g586184.jpg
<DESCRIPTION>G586184.JPG
<TEXT>
begin 644 g586184.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!$35),3%]'4D%02$E#4SI;4%1#7U1(
M15)!4$555$E#4U])3D-=5TE,34527T-55$Q%4E].64-?2U]&3T]415(N15!3
M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_\  $0@ '0)Z P$B  (1 0,1 ?_$ !X   ,  P$  P$           8'
M"  %"00! @,*_\0 -A   @,  P ! P0! @0#"0  !08#! <! @@) !05$1,6
M%Q(Q@1@A49%!86(9)"8R<9*AL<'_Q  4 0$                     _\0
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MPIZ?]:5<;;<>S2G2T3+<6(8,RV=?I&H#YAVK-]=8T.H+SE$JLPH*U#&EE(.
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MXT\6:5G"#IM17%4Y2&I:#ZIZF-)60B^8/% O5P6U-+&EQ#U9#N0HBMR#RRF
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M*G*UR5K%+M1S>:JC4<C#FOYX/=F<,E! P0E^.A"3AWR.@&7?\-]$&3&QXCY
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MSU[Y5D'-_.^3;&ZZ[Z#]%.B=E[ _'%_.UXJ<#3;OH;(F9@2= Z *30(,4PG
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MYVG*:"H#_P 2J)"T!4%D7]S;N?C5Y9$U @6A]W?GLW;7V8RC5K?<W+$]J?\
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M$%YW0&[TZC^<75S6>J:[G6!?[@R[9SW B=1#H+&>BL!VH(L,*A+:NQTAY?\
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MNOY7L9RP,-_][ANU>!A G^M7K9YJVZRE?_>.49LRN@MD5M-X4D@@\J=W4QX
M!>0R^IYWDQG;&;(5Z/JUQNQ)WAS]>,VA]SNG540LQC["(.<[#KTY!?3TVK"T
M7<QZ37<Y6P?>S=ZKZ.BL2.YL:(T++A"K-:1W*#SJQ?'W>8[:B[M8"]0M=K(^
MW1,S\RU>;$56>NDIO!GGTF9ND#\&C,]4N'/]#"\Q:L^DE@LUM>;WL=8]3O!.
MQR.MVULSF)4HGWG^OS7,25"9$KUYZ,MVP<D ,G^0Q-[!>*U+%=[_ +4NWS$0
M?%K2V@\:#=6A.3B-EGTKKUBT_E-E1:J6Q+\M^"NZ=WF%D*0Y_P!$Z1\Y_ ?0
M[GWR3(1M&56ENSW3ZM$@CRR%] 65&@0S0EM:Q@O&]:)AZA%W;K#_ "N -;H,
MM(;,<5:">5:EXKG-%WO/XVT#Y?FA>,L)T'CK:OB6U<-\3T..C4AZ&[)39#0K
M(/\ 5=P)680)NJ1I@SN?<QKI\94EAA)=Z8EAY_:; ((^,%P'@3S<NF*LXP&Z
M=%T<NS"1F>6=+>[F<C3%_+OZ3*Z#24[)V2I'I9C*^9U$JZ=Y)"=OJ1.L7/\
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MZ##S3NBIKM>74(Z2%:-0)*!E?<U)5.=Q%(K56%^F<V]#P=Y\\Z-'/%7/LKT
MKT8ERV E!<:T(-' R4;BMR=NX[15P<%[2/B=+QR03I28:L5[<6"$<759+_@S
MSN,2*F?F1S\_JX=\RYY6Z.C:KH+?W5;.)7X;>4K:Y8OL'64<EJ$,<@GNL\\S
M4V\'=*B-![-U,N3CMOW*L4S3%('RMFBU&M0Z7I[KL3KUZ$"A#DSH>@7XB#6>
M[]BMV[WJ<$+,$/[ RCVK"!D$4=071IU>G6'@(,;/=FFYSL9#!&[)IS3^JZ90
ME(]T<-:GIZ5C&P7&P=Y:K99_)VI> 1:SI#$"9E!T@;7.@IYQ#@&[Z6W3+R#:
MSJR:VNB?)7GRTC'F\8HN*W10 B<V[,T:H%%*Z+A@6UZ1N>?G]>TPK&X<VH'A
M9()^FV(:JC WKWVRT/:Y#ME,-""A6I]3\N8_K)5K:644>'NK. RX)W>55M8E
MEL7^<4:GQURPVI$A9"*-=8E!DTIUN0E:57CN;H'KJZT1'5F:0-WU*MX[P%55
M[*K34B!.@5J)L+)<9&MH8S+?<3-99MS'G&\L8+6[C$?*ZPY-#DV%"7>:9KN&
MK8\[Q<"=:XN 'JBM]5]4PKA0$L 0>P5NY ;0:1,@(]^,DL3=1EZ^%L2=[PG\
MO0Z5B]4<5CIFJE*]6A-BQ!;I<%U"WZ!<VSI6R=.%(*36O4%,#(2Z@1-TN4-=
M 8X@5NE(@ FR8MWKE-;"=KO<8K@8['XQ77JHU;!5Z(,4.H5CKZ#X[<_IQSS_
M -..>?\ MQ]<AK/N[;*WIC;T6@ 6FU Q;T'1RT\@K^'[1&VT,HJX7F>K.&T$
M/2O+)>P2K?5KCY>YDS8\O+=LH+&#PM=BJLYD9Q>Z]<\<<\<\<_Z<\?IS_P#3
MGZ11?SACQI1WI((*W>=;]*%6 [L5'DR;_P F<NRHBOG):]7L<D.9P,LBDF+=
M"OT R#H:=D;U)U8HB-BW9G"*PWRAYDT7$(TN+AP@J,]'9E.VL#Y%!LT4KNR+
MHOF%$0LQ1"Z,_,>1M/+SSZ'K7.AX>^W%2G6@B)F&Q;' &OM2NG%=H6]O4R+&
M#&GUPFMM;.@/*2V5Q=9M0WU-(<CF528HP1=@7[%X?+VK6JI1;8#ZV>#D!9Y>
M-E0Q.E=F0E/P#YSZ "- F/T-E8"AME<;.CLVL:$6TRN]M)7'6$B^!7#N?BNK
M+52/X)DY=;N+,8BDI3*G2DM#Q08J:&$:&QW'TO$TN),2H2TE6<P<:#QUD-$&
M5O<&]H)S&69O<6<K-.3/L9TG/WGN7+4O$-:M'3$"JHX(-&C*8<^3OR*7QNQ>
MJ46E6RNPK9EDNX%<0O<M':RWL^P>65ND5W=;T%9J&.;M!9_*-@8:D]A5.@6L
M0YGK=TI9_9D6.>&50^08=(7?5";SSO!=_3-,=4(0E)P[/#C!H2WF.:YCH^D:
MZKUKFC"!U)#6*^KJ ;K0.FJ3D?.L"VO*J^P,IB0,.;]CQ#Y?G3UA+[Y4*C%*
MEMJO#"%0@9I-EBX^+KVK/5@ZZTR$#8RR.H33'FJV?R R2ZGYF*[>)=9[W2M8
M@TCKX;Q)P.,[-VNZBJL3*TR-=H\AZFWIYH;<-Y^J9<[BP!4/?AOA5S1TE&4*
M#POTY^HT@:6PCL+A#O@RDSP!4:*ZK6DI*AHB81X,*#XK@')5+<5;E+@HN,XF
MH;"$.*9""K?J?>#;U:QS5O5:URMVDY@M5X9XY(NI5]:!45EY'5UQ+4A-, JJ
M($.KK((='^R."+Z^.K"0HBA!_EV_9I#1M.M2JQ?Y<_MP0].O////'//._P#H
M!%_LN--%<[6=U U]_K*C'.CT6/BUV7[CA"&NR+%0YUHVZ%WL'LG.M" GUJ7J
M5KM2DGXKVZ\W/2;IRF'_ "=F2_'1^&IRC)B=[RIRX!B\I A_*+GK^/$*?I>?
M"+4T%^8#4#P8^1I1]_V^UEG[//%T#QTXYJ\\2=AN>..?]?\ KQS_ +\<\<\?
M]N>..?J1(_"OEN//A.8=,RZ=4H'Z-C]5B17\H<.TM+<(M&L:7T:(2?<]W*<"
MN&&W9'?POFYRE\H\W?.N0'*+SRO_ $""I_)SER\MZE6T=99H-(P>KG([302M
M9S64'<971V(9/=O#S)'5NP?)T\;IH$W0O$?2;#D$JVM=@S.Q20!RM2_/O /O
MRN4T4JLE,S>PB&8&X;RF:CPN@C"TK,6YY44?5A8U*(;HLA?N4MEAT8*O=1A1
MQ+I3D0D1QV&U6$0;F-5WX_\ !$N)Q[)!+9DJ^Q_;5QA15VW1Q-K/Q@_0S^JT
M06=U8SG<.O+\;^W,YT@&G&$Z++ 9E7FV$^KCPH06S5#R!Y]1U48FKB-]BOB9
M\PLU:7)Y@E_6WD-+I11;<TDA/GO+./B_<F(<]N?\#ENQ:MF.EV>Q)W[ BU_Y
M%\H[#82S.NZA42!ZS#<-[CVSZD$R^\TUO,0?UF07@Z__ #MFTJN0N8X0N,@Z
MOV73 2N7&7\^D<"#I7JTB/UG^1!<'FUX,QX%O"-S_8,R9J-EZI9F)CQT-QYS
M;_355\8Y NELE-D79\^4+\ENJCW6$Z'(5300F,A:@O\ &R#J+^/,/FS4AF8%
M0&B!$O0E9#PE>2K8('';7GFUY@HDB0 V8[U60=2Q^:)8LKI2Q^**PP\W;?3@
MS-W*_4Y>??!*L(4R-_6WD]JS(P:LNZ%9O<7WZF)E[I&,7?-W*V8J:/IFR,[6
MN-V<D7 ,X!&ET+@R UI[4QH@1:%UR<X&<7R#J4WX,+UP/TE%IK<<2J"/CUQ4
MSH>^N*[I"'J>B(C^/M7]4K(8-0.@<9T.M=Y<75<9DQB!\++\LK!J_0JV:&1/
M3.-:"CIK\&;ZU,0[JB\WBJ9RO9%&JHUE$4S5&L8%RQR2#2D%6[%$0H222=Z=
MOK-7[]^W:/GMR$YAXRP[,2X=E%TG=G9U<^ ,*S-HFDN[Z>6JJ<DO^<IBN&(L
M9NY)73E).U)_&!UZ7B>M)=:2S&8[E6BQR:X*UGROABBN+ZH 39*0%8""EX)2
H[,3/:[5! 6A -&U>UJV8GM6>:].M#%S/9FFL3<]/W)I9).W;OR'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
